Neurodenerative Movement Disorders - Ferguson Flashcards
hypokinesia
decreased bodily movement
-associated with diseases of basal ganglia
name a prototypical hypokinetic movement
Parkinson’s disease
Parkinsonisms
diseases which have similar initial presentations to Parkinson’s disease
-but different clinical course and underlying pathology
What part of the brain does Parkinson’s disease impact
substantia nigra neurons die prematurely
- loss of pigmented dopaminergic cells
- accumulation to Lewy bodies and Lewy Neurites
how does a patient get categorized as idiopathic or primary Parkinson’s disease
neurodegeneration in susbtantia nigra and locus coreuleus
what categorizes secondary Parkinson’s disease
some clear cause of the Parkinson’s disease
what infections can cause Parkinson’s disease
epidemic of encephalitis
Von Economo’s Encephalitis
what toxins can cause Parkinson’s disease
carbon monoxide
carbon disulfide
manganese
L-BMAA toxicity
what designer drug can cause Parkinson’s ? what drug was it trying to mimic
MPTP byproduct of meperidine (Demerol)
WHAT DIABETIC GASTROPARESIS HAS MANY FEATURES OF NEUROLEPTICS AND CAUSES SECONDARY PARKINSON’S DISEASE
Metaclopramide ( Reglan)
what type of prescription drugs cause Parkinson
Neuroleptics ( haloperidol/chlorpromazine (throazine))
reserpine ( deplete dopamine)
what is different about acute trauma that induces Parkinsonism
may be reversible
what are the clinical features of Parkinson’s disease
TRAP
tremor, rigidity, akinesia, postural instability
what type of tremor is found in Parkinson’s disease
rest tremor
asymmetric onset
pill rolling or wrist supination/pronation
describe the rigidity of Parkinson’s disease
“cogwheeling” : extension and flexion at elbow and wrist common, ratchet-like feeling
what is akinesia
loss or impairment of the power of voluntary movement.
“freeze”
what are other signs of Parkinson
gait impairment hallucinations (late in disease) REM sleep behavior disorder dementia autonomic dysfunction: constipation, urinary frequency, sweating
what is the gold standard to treat Parkinson
Carbidopa/Levodopa (Sinemet)
MAO of Carbidopa/Levodopa
crosses BBB and converts to dopamine by ALLA-decarboxylase
what are disadvantages Carbidopa/Levodopa
short half life
competes with amino acids in GI and BBB
motor fluctuations
MOA of MAO-B inhibitors
selective inhibition of MAO-B enzyme involved in dopamine metabolism
what are drawbacks for MAO-B inhibitors
tons of drug interactions
very mild anti-Parkinson drug